343 related articles for article (PubMed ID: 24552678)
1. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.
Baldur-Felskov B; Dehlendorff C; Munk C; Kjaer SK
J Natl Cancer Inst; 2014 Mar; 106(3):djt460. PubMed ID: 24552678
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
Verdoodt F; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
[TBL] [Abstract][Full Text] [Related]
4. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
7. High-grade cervical lesions after vaccination against human papillomavirus: A Danish cohort study.
Thamsborg LH; Napolitano G; Larsen LG; Lynge E
Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1290-1296. PubMed ID: 32754966
[TBL] [Abstract][Full Text] [Related]
8. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program.
Baldur-Felskov B; Dehlendorff C; Junge J; Munk C; Kjaer SK
Cancer Causes Control; 2014 Jul; 25(7):915-22. PubMed ID: 24797870
[TBL] [Abstract][Full Text] [Related]
9. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
Sand FL; Kjaer SK; Frederiksen K; Dehlendorff C
Int J Cancer; 2020 Aug; 147(3):641-647. PubMed ID: 31648368
[TBL] [Abstract][Full Text] [Related]
10. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
11. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
12. Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
Lei J; Ploner A; Lehtinen M; Sparén P; Dillner J; Elfström KM
Br J Cancer; 2020 Jul; 123(1):155-160. PubMed ID: 32362659
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination.
Dong L; Nygård M; Støer NC; Klungsøyr O; Hansen BT
Int J Cancer; 2023 Jul; 153(2):399-406. PubMed ID: 36866965
[TBL] [Abstract][Full Text] [Related]
14. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
[TBL] [Abstract][Full Text] [Related]
15. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries.
Kjaer SK; Nygård M; Dillner J; Brooke Marshall J; Radley D; Li M; Munk C; Hansen BT; Sigurdardottir LG; Hortlund M; Tryggvadottir L; Joshi A; Das R; Saah AJ
Clin Infect Dis; 2018 Jan; 66(3):339-345. PubMed ID: 29029053
[TBL] [Abstract][Full Text] [Related]
16. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
18. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
[TBL] [Abstract][Full Text] [Related]
20. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
